NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis $9.70 +0.23 (+2.43%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.49▼$9.7650-Day Range$8.14▼$9.6752-Week Range$7.52▼$10.95Volume398,111 shsAverage Volume365,422 shsMarket Capitalization$1.24 billionP/E Ratio323.44Dividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enfusion alerts: Email Address Enfusion MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside3.8% Downside$9.33 Price TargetShort InterestBearish4.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 4 Articles This WeekInsider TradingSelling Shares$296,688 Sold Last QuarterProj. Earnings Growth122.22%From $0.09 to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 starsComputer And Technology Sector534th out of 612 stocksPrepackaged Software Industry182nd out of 202 stocks 0.8 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageEnfusion has only been the subject of 1 research reports in the past 90 days.Read more about Enfusion's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.85% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Enfusion has recently increased by 21.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 2.5 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enfusion this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Enfusion to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $296,688.00 in company stock.Percentage Held by Insiders36.44% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enfusion's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 122.22% in the coming year, from $0.09 to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 323.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 323.44, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 262.26.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 15.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enfusion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesJuly 24 at 2:14 AM | americanbankingnews.comAnalysts Set Enfusion, Inc. (NYSE:ENFN) Price Target at $9.33July 20, 2024 | finance.yahoo.comEnfusion, Inc. (ENFN)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 15, 2024 | seekingalpha.comEnfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy RatingJune 13, 2024 | businesswire.comFTV Capital Expands Internationally with Opening of London OfficeMay 29, 2024 | businesswire.comEnfusion To Present at Upcoming Investor EventsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enfusion on Strong Growth and Market Positioning ProspectsMay 22, 2024 | finance.yahoo.comInsider Sale: Chief People Officer Bronwen Bastone Sells 34,059 Shares of Enfusion Inc (ENFN)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q1 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q1 2024 Earnings Call TranscriptMay 11, 2024 | finance.yahoo.comEnfusion First Quarter 2024 Earnings: EPS Misses ExpectationsMay 9, 2024 | msn.comENFN Stock Earnings: Enfusion Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comEnfusion Announces First Quarter 2024 ResultsMay 7, 2024 | finance.yahoo.comHas Enfusion, Inc.'s (NYSE:ENFN) Impressive Stock Performance Got Anything to Do With Its Fundamentals?April 18, 2024 | businesswire.comEnfusion Announces Date of First Quarter 2024 ResultsApril 17, 2024 | morningstar.comEnfusion Inc Class AApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNSee More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside-3.2%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio321.44 Forward P/E Ratio107.11 P/E Growth2.14Net Income$6.03 million Net Margins1.40% Pretax Margin3.04% Return on Equity6.60% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual Sales$181.62 million Price / Sales6.80 Cash Flow$0.15 per share Price / Cash Flow63.83 Book Value$0.61 per share Price / Book15.80Miscellaneous Outstanding Shares128,110,000Free Float81,427,000Market Cap$1.23 billion OptionableOptionable Beta0.92 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 53)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 51)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMs. Valeria Gutowski (Age 42)Chief Accounting Officer Mr. Daniel Groman (Age 35)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMr. Joseph DefeoGlobal Head of Managed Services ProductionMr. Jeff YoungHead of ImplementationMr. Robert TaylorHead of Client SupportMore ExecutivesKey CompetitorsPowerSchoolNYSE:PWSCZeta GlobalNASDAQ:ZETAACI WorldwideNASDAQ:ACIWZoomInfo TechnologiesNASDAQ:ZIBrazeNASDAQ:BRZEView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 36,257 shares on 7/26/2024Ownership: 0.125%RiverPark Advisors LLCBought 8,008 shares on 7/26/2024Ownership: 0.006%Gladius Capital Management LPBought 26,755 shares on 7/19/2024Ownership: 0.021%Bronwen BastoneSold 18,241 sharesTotal: $147,934.51 ($8.11/share)Bronwen BastoneSold 10,539 sharesTotal: $86,103.63 ($8.17/share)View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions How have ENFN shares performed this year? Enfusion's stock was trading at $9.70 on January 1st, 2024. Since then, ENFN shares have increased by 0.0% and is now trading at $9.70. View the best growth stocks for 2024 here. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by $0.05. The company earned $48.05 million during the quarter, compared to analysts' expectations of $47.67 million. Enfusion had a net margin of 1.40% and a trailing twelve-month return on equity of 6.60%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share. Who are Enfusion's major shareholders? Top institutional investors of Enfusion include Bank of New York Mellon Corp (0.12%), Gladius Capital Management LP (0.02%) and RiverPark Advisors LLC (0.01%). Insiders that own company stock include Oleg Movchan, Bronwen Bastone, Dan Groman, Matthew Campobasso, Deirdre Somers, Valeria Gutowski, Tarek Hammoud, Stephen Malherbe, Hillhouse Investment Managemen and Roy Luo. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
